The high-density fermentation process for
producing ultra-high purity NMN (β-Nicotinamide Mononucleotide CAS No.: 1094-61-7) using nicotinamide riboside kinase (NRK)
represents a groundbreaking approach in production methodologies. NRK exhibits
heightened enzymatic activity, thereby reducing the production costs associated
with NRK kinase and improving the catalytic efficiency of NMN synthesis. This
advancement effectively addresses the challenge of high catalyst preparation
costs in the NMN production process. Achieving a conversion rate as high as
98%, coupled with NMN purity levels reaching up to 99.99%, underscores the
efficacy of this innovative method.
The fermentation process is structured into
two distinct stages, facilitating high-density fermentation in recombinant NRK
gene-engineered bacteria. This approach not only enhances the cell density of
engineered bacteria producing NRK, with cell density reaching a maximum OD600
of 270 and wet cell weight of 300g/L, but also elevates the enzymatic activity
of NRK. Consequently, the fermentation broth yields NRK activity exceeding
105U/mL, a testament to the effectiveness and efficiency of this process.
This breakthrough production method holds immense
promise for various applications, particularly in the pharmaceutical and
nutraceutical industries. With its ability to produce ultra-high purity NMN at
significantly reduced costs, it paves the way for widespread utilization of NMN
in medical treatments, dietary supplements, and other health-related products.
Furthermore, the scalability and efficiency of this process make it a viable
solution for meeting increasing market demands for NMN, thus driving
advancements in healthcare and wellness. Continued research and optimization of
this method are expected to further enhance its capabilities and broaden its
potential applications in the future.